Christopher Missling is the founder of Anavex. Anavex has raised $3M in total funding. Latest round: Growth. Backed by Lincoln Park Capital Fund, LLC.
Christopher Missling is the Chief Executive Officer and a board member at Anavex. The company focuses on developing therapies, with a lead drug candidate, ANAVEX 2-73, aimed at treating Alzheimer's disease. Missling has over 20 years of healthcare industry experience, including roles at large pharmaceutical companies, biotech firms, and investment banking.
Full founder directory · Investor directory · Company funding database · Fundraising library